Abstract | OBJECTIVE: METHODS: A total of 118 patients with RMS were randomly assigned 1:1:1 to receive oral placebo or teriflunomide, 7 or 14 mg, once daily for 24 weeks; 86 patients entered the 24-week extension. The primary objective was to evaluate safety; secondary objectives were to evaluate the effects of treatment on disease activity assessed by MRI and relapse rate. RESULTS:
Teriflunomide was well tolerated with a low and similar incidence of treatment-emergent adverse events (TEAEs) across the 3 groups; TEAEs led to treatment discontinuation of 4.9%, 8.1%, and 7.9% of patients in the placebo, 7-mg, and 14-mg groups, respectively. The number of gadolinium-enhancing T1 (T1-Gd) lesions was reduced in both teriflunomide groups, with relative risk reductions (RRRs) of 84.6% (p = 0.0005) and 82.8% (p < 0.0001) for 7 and 14 mg, respectively, compared with IFNβ alone at 48 weeks. T1-Gd lesion volume was also reduced in the 7-mg group (RRR 72.1%, p = 0.1104) and 14-mg group (RRR 70.6%, p = 0.0154). A trend toward dose-dependent reduction in annualized relapse rate was also noted (RRRs 32.6% [p = 0.4355] and 57.9% [p = 0.1005] for 7 and 14 mg, respectively). CONCLUSION:
Teriflunomide as add-on therapy to IFNβ had acceptable safety and tolerability and reduced MRI disease activity compared with IFNβ alone. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that teriflunomide, 7 and 14 mg, added to IFNβ, is safe. The T1-Gd lesion burden was significantly reduced with both teriflunomide doses.
|
Authors | M S Freedman, J S Wolinsky, B Wamil, C Confavreux, G Comi, L Kappos, T P Olsson, A Miller, H Benzerdjeb, H Li, C Simonson, P W O'Connor, Teriflunomide Multiple Sclerosis Trial Group and the MRI Analysis Center |
Journal | Neurology
(Neurology)
Vol. 78
Issue 23
Pg. 1877-85
(Jun 05 2012)
ISSN: 1526-632X [Electronic] United States |
PMID | 22622860
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Crotonates
- Hydroxybutyrates
- Nitriles
- Toluidines
- teriflunomide
- Interferon-beta
|
Topics |
- Adult
- Crotonates
(administration & dosage, adverse effects)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Humans
- Hydroxybutyrates
- Interferon-beta
(administration & dosage)
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Multiple Sclerosis, Relapsing-Remitting
(drug therapy, immunology)
- Nitriles
- Severity of Illness Index
- Toluidines
(administration & dosage, adverse effects)
- Treatment Outcome
|